New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 3, 2013
13:38 EDTBMY, SHPG, BIIBUnclear if pipeline alone can restore Bristol's growth, WSJ says
With Bristol-Myers' (BMY) losing Plavix patent exclusivity, the company took a 17% hit in revenues in 2012, and is now counting on new drugs like Eliquis and late-stage drugs aiming to treat cancer, diabetes and hepatitis C to restore growth, says the Wall Street Journal. However, "it remains unclear whether new drugs alone will be enough to restore growth," says WSJ, adding that in recent months Bristol has studied the possibility of Biogen Idec (BIIB) Shire (SHPG) as possible acquisition targets. Reference Link
News For BMY;SHPG;BIIB From The Last 14 Days
Check below for free stories on BMY;SHPG;BIIB the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 21, 2014
13:32 EDTBMYBristol-Myers, Pfizer announce approval of Eliquis for treatment of DVT, PE
Subscribe for More Information
August 20, 2014
08:03 EDTBMYBristol-Myers Pfizer to present new Eliquis data
Subscribe for More Information
08:02 EDTBMYBristol-Myers, Celgene enter collaboration agreement for OPDIVO, ABRAXANE
Subscribe for More Information
August 18, 2014
07:57 EDTSHPG, BMYCambridge Healthtech Institute to hold a summit
6th Annual Bioprocessing Summit to be held in Boston on August 18-22.
August 15, 2014
18:35 EDTBIIBBiogen PLEGRIDY approved in U.S. for treatment of multiple sclerosis
Biogen Idec announced that the FDA has approved PLEGRIDY, a new treatment for people with relapsing forms of multiple sclerosis, or RMS. PLEGRIDY is dosed once every two weeks and can be administered subcutaneously with the PLEGRIDY PEN, a new, ready-to-use autoinjector, or a prefilled syringe. The FDA approval of PLEGRIDY is based on results from one of the largest pivotal studies of beta interferon conducted, ADVANCE, which involved more than 1,500 MS patients.
07:01 EDTBIIBIsis Pharmaceuticals earns $2M from advancement of ISIS-SMN from Biogen
Isis Pharmaceuticals (ISIS) announced that it has earned a $2M milestone payment from Biogen (BIIB) related to the advancement of the ongoing open-label extension study of ISIS-SMNRx in children with spinal muscular atrophy.
August 14, 2014
17:16 EDTSHPGPaulson & Co gives quarterly update on stakes
Subscribe for More Information
August 12, 2014
11:24 EDTSHPGOptions with increasing implied volatility
Subscribe for More Information
August 11, 2014
10:50 EDTBIIBBiogen weakness attributed to Forward Pharma IPO filing
Shares of Biogen Idec (BIIB) came off their earlier highs and moved into negative ground in early trading, with some attributing the move lower to another pharmaceutical company, Forward Pharma (FWP), filing its registration statement with the SEC relating to a proposed initial public offering and reporting that Joel Sendek has been appointed CFO. WHAT'S NOTABLE: Forward Pharma focuses on a proprietary formulation of dimethyl fumarate, or DMF, for the treatment of multiple sclerosis. DMF is the Active Pharmaceutical Ingredient, or API, found in Tecfidera, which Biogen Idec began selling for the treatment of RRMS following approval by the FDA in March 2013 and approval by the European Commission in February 2014, Forward Pharma indicated in its IPO filing. In addition to its filing, Forward Pharma announced this morning that it has hired Joel Sendek from Stifel Financial, where he served as Managing Director, Biotechnology and led the firm's healthcare equity research group. PRICE ACTION: Shares of Biogen are down fractionally in mid-morning trading after being up over 1% soon after today's opening bell.
August 8, 2014
10:36 EDTSHPGOptions with increasing implied volatility
Subscribe for More Information
10:03 EDTBMYBristol-Myers Hodgkin lymphoma treatment granted orphan drug status
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use